SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of Commencement of a Class Ac...
September 06 2016 - 10:43AM
Business Wire
The following statement is being issued by Levi & Korsinsky,
LLP:
To: All persons or entities who purchased or otherwise
acquired securities of Keryx Biopharmaceuticals, Inc. (NASDAQ:
KERX) between February 25, 2016 and August
1, 2016. You are hereby notified that a
securities class action lawsuit has been commenced in the USDC for
the Southern District of New York. To get more information go
to:
http://www.zlk.com/pslra/keryx-biopharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at
jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877)
363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period,
Defendants made materially false and/or misleading statements, as
well as failed to disclose material adverse facts about the
Company’s business, operations, and prospects. Specifically,
Defendants made false and/or misleading statements and/or failed to
disclose: (1) that the Company was experiencing production-related
difficulties in converting API to finished drug product; (2) that
the issue was resulting in decreased production yields of finished
drug product; (3) that, as a result, the Company would, and did
exhaust its reserve of finished drug product; and (4) that, as a
result of the foregoing, Defendants’ statements about Keryx’s
business, operations, and prospects, were false and misleading
and/or lacked a reasonable basis.
If you suffered a loss in Keryx Biopharmaceuticals, Inc. you
have until October 3, 2016 to
request that the Court appoint you as lead plaintiff. Your ability
to share in any recovery doesn’t require that you serve as a lead
plaintiff.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience
representing investors in securities litigation, and have recovered
hundreds of millions of dollars for aggrieved shareholders.
Attorney advertising. Prior results do not guarantee similar
outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160906006030/en/
Levi & Korsinsky, LLPJoseph E. Levi, Esq.Tel:
212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024